Connection
Marc Bonaca to Hospital Mortality
This is a "connection" page, showing publications Marc Bonaca has written about Hospital Mortality.
|
|
Connection Strength |
|
|
|
|
|
0.301 |
|
|
|
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
Score: 0.142
-
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
Score: 0.134
-
Isselbacher EM, Bonaca MP, Di Eusanio M, Froehlich J, Bossone E, Sechtem U, Pyeritz R, Patel H, Khoynezhad A, Eckstein HH, Jondeau G, Ramponi F, Abbasi M, Montgomery D, Nienaber CA, Eagle K, Lindsay ME. Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection. Circulation. 2016 10 04; 134(14):1013-1024.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|